nodes	percent_of_prediction	percent_of_DWPC	metapath
Nevirapine—CYP2A6—Tamoxifen—pancreatic cancer	0.0897	0.115	CbGbCtD
Nevirapine—CYP2A6—Fluorouracil—pancreatic cancer	0.0661	0.0848	CbGbCtD
Nevirapine—CYP2B6—Tamoxifen—pancreatic cancer	0.0584	0.0749	CbGbCtD
Nevirapine—CYP3A5—Tamoxifen—pancreatic cancer	0.046	0.059	CbGbCtD
Nevirapine—CYP2B6—Irinotecan—pancreatic cancer	0.0448	0.0575	CbGbCtD
Nevirapine—CYP1A2—Dacarbazine—pancreatic cancer	0.043	0.0552	CbGbCtD
Nevirapine—CYP3A5—Erlotinib—pancreatic cancer	0.0391	0.0502	CbGbCtD
Nevirapine—CYP3A5—Irinotecan—pancreatic cancer	0.0353	0.0453	CbGbCtD
Nevirapine—CYP1A2—Tamoxifen—pancreatic cancer	0.0342	0.0439	CbGbCtD
Nevirapine—CYP2C9—Tamoxifen—pancreatic cancer	0.0309	0.0396	CbGbCtD
Nevirapine—CYP1A2—Erlotinib—pancreatic cancer	0.0291	0.0374	CbGbCtD
Nevirapine—CYP2D6—Tamoxifen—pancreatic cancer	0.0282	0.0362	CbGbCtD
Nevirapine—CYP3A5—Docetaxel—pancreatic cancer	0.0259	0.0332	CbGbCtD
Nevirapine—CYP3A5—Sunitinib—pancreatic cancer	0.0258	0.0331	CbGbCtD
Nevirapine—CYP1A2—Fluorouracil—pancreatic cancer	0.0252	0.0324	CbGbCtD
Nevirapine—CYP2B6—Doxorubicin—pancreatic cancer	0.0245	0.0314	CbGbCtD
Nevirapine—CYP2D6—Erlotinib—pancreatic cancer	0.024	0.0308	CbGbCtD
Nevirapine—CYP2C9—Fluorouracil—pancreatic cancer	0.0227	0.0292	CbGbCtD
Nevirapine—CYP3A4—Tamoxifen—pancreatic cancer	0.0179	0.023	CbGbCtD
Nevirapine—CYP3A4—Erlotinib—pancreatic cancer	0.0153	0.0196	CbGbCtD
Nevirapine—CYP3A4—Irinotecan—pancreatic cancer	0.0138	0.0177	CbGbCtD
Nevirapine—CYP2D6—Doxorubicin—pancreatic cancer	0.0118	0.0152	CbGbCtD
Nevirapine—CYP3A4—Docetaxel—pancreatic cancer	0.0101	0.013	CbGbCtD
Nevirapine—CYP3A4—Sunitinib—pancreatic cancer	0.01	0.0129	CbGbCtD
Nevirapine—CYP3A4—Doxorubicin—pancreatic cancer	0.00752	0.00966	CbGbCtD
Nevirapine—Agranulocytosis—Docetaxel—pancreatic cancer	0.000309	0.0014	CcSEcCtD
Nevirapine—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—pancreatic cancer	0.000308	0.0014	CcSEcCtD
Nevirapine—Asthenia—Erlotinib—pancreatic cancer	0.000307	0.00139	CcSEcCtD
Nevirapine—Dermatitis exfoliative—Epirubicin—pancreatic cancer	0.000307	0.00139	CcSEcCtD
Nevirapine—Discomfort—Gemcitabine—pancreatic cancer	0.000306	0.00139	CcSEcCtD
Nevirapine—Pruritus—Tamoxifen—pancreatic cancer	0.000306	0.00139	CcSEcCtD
Nevirapine—Anaphylactic shock—Irinotecan—pancreatic cancer	0.000305	0.00138	CcSEcCtD
Nevirapine—Oedema—Irinotecan—pancreatic cancer	0.000305	0.00138	CcSEcCtD
Nevirapine—Myalgia—Fluorouracil—pancreatic cancer	0.000305	0.00138	CcSEcCtD
Nevirapine—Gastrointestinal pain—Sunitinib—pancreatic cancer	0.000303	0.00137	CcSEcCtD
Nevirapine—Dermatitis bullous—Epirubicin—pancreatic cancer	0.000303	0.00137	CcSEcCtD
Nevirapine—Pruritus—Erlotinib—pancreatic cancer	0.000303	0.00137	CcSEcCtD
Nevirapine—Discomfort—Fluorouracil—pancreatic cancer	0.000301	0.00137	CcSEcCtD
Nevirapine—Nervous system disorder—Irinotecan—pancreatic cancer	0.000299	0.00136	CcSEcCtD
Nevirapine—Thrombocytopenia—Irinotecan—pancreatic cancer	0.000299	0.00135	CcSEcCtD
Nevirapine—Hepatic failure—Doxorubicin—pancreatic cancer	0.000298	0.00135	CcSEcCtD
Nevirapine—Anaphylactic shock—Gemcitabine—pancreatic cancer	0.000297	0.00135	CcSEcCtD
Nevirapine—Oedema—Gemcitabine—pancreatic cancer	0.000297	0.00135	CcSEcCtD
Nevirapine—Hepatitis—Docetaxel—pancreatic cancer	0.000297	0.00135	CcSEcCtD
Nevirapine—Diarrhoea—Tamoxifen—pancreatic cancer	0.000296	0.00134	CcSEcCtD
Nevirapine—Abdominal pain—Sunitinib—pancreatic cancer	0.000293	0.00133	CcSEcCtD
Nevirapine—Body temperature increased—Sunitinib—pancreatic cancer	0.000293	0.00133	CcSEcCtD
Nevirapine—Diarrhoea—Erlotinib—pancreatic cancer	0.000293	0.00133	CcSEcCtD
Nevirapine—Anaphylactic shock—Fluorouracil—pancreatic cancer	0.000292	0.00132	CcSEcCtD
Nevirapine—Oedema—Fluorouracil—pancreatic cancer	0.000292	0.00132	CcSEcCtD
Nevirapine—Connective tissue disorder—Docetaxel—pancreatic cancer	0.000292	0.00132	CcSEcCtD
Nevirapine—Nervous system disorder—Gemcitabine—pancreatic cancer	0.000292	0.00132	CcSEcCtD
Nevirapine—Thrombocytopenia—Gemcitabine—pancreatic cancer	0.000291	0.00132	CcSEcCtD
Nevirapine—Anorexia—Irinotecan—pancreatic cancer	0.000291	0.00132	CcSEcCtD
Nevirapine—Skin disorder—Gemcitabine—pancreatic cancer	0.000289	0.00131	CcSEcCtD
Nevirapine—Nervous system disorder—Fluorouracil—pancreatic cancer	0.000287	0.0013	CcSEcCtD
Nevirapine—Thrombocytopenia—Fluorouracil—pancreatic cancer	0.000286	0.0013	CcSEcCtD
Nevirapine—Dermatitis exfoliative—Doxorubicin—pancreatic cancer	0.000284	0.00129	CcSEcCtD
Nevirapine—Anorexia—Gemcitabine—pancreatic cancer	0.000283	0.00128	CcSEcCtD
Nevirapine—Erythema multiforme—Docetaxel—pancreatic cancer	0.000281	0.00127	CcSEcCtD
Nevirapine—Dermatitis bullous—Doxorubicin—pancreatic cancer	0.00028	0.00127	CcSEcCtD
Nevirapine—Face oedema—Epirubicin—pancreatic cancer	0.00028	0.00127	CcSEcCtD
Nevirapine—Anorexia—Fluorouracil—pancreatic cancer	0.000279	0.00126	CcSEcCtD
Nevirapine—Vomiting—Tamoxifen—pancreatic cancer	0.000275	0.00125	CcSEcCtD
Nevirapine—Paraesthesia—Irinotecan—pancreatic cancer	0.000274	0.00124	CcSEcCtD
Nevirapine—Hypersensitivity—Sunitinib—pancreatic cancer	0.000273	0.00124	CcSEcCtD
Nevirapine—Rash—Tamoxifen—pancreatic cancer	0.000273	0.00124	CcSEcCtD
Nevirapine—Dermatitis—Tamoxifen—pancreatic cancer	0.000273	0.00124	CcSEcCtD
Nevirapine—Vomiting—Erlotinib—pancreatic cancer	0.000272	0.00123	CcSEcCtD
Nevirapine—Somnolence—Irinotecan—pancreatic cancer	0.000271	0.00123	CcSEcCtD
Nevirapine—Headache—Tamoxifen—pancreatic cancer	0.000271	0.00123	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Gemcitabine—pancreatic cancer	0.000271	0.00123	CcSEcCtD
Nevirapine—Rash—Erlotinib—pancreatic cancer	0.00027	0.00122	CcSEcCtD
Nevirapine—Dermatitis—Erlotinib—pancreatic cancer	0.00027	0.00122	CcSEcCtD
Nevirapine—Immune system disorder—Docetaxel—pancreatic cancer	0.000268	0.00122	CcSEcCtD
Nevirapine—Headache—Erlotinib—pancreatic cancer	0.000268	0.00122	CcSEcCtD
Nevirapine—Liver function test abnormal—Epirubicin—pancreatic cancer	0.000267	0.00121	CcSEcCtD
Nevirapine—Paraesthesia—Gemcitabine—pancreatic cancer	0.000267	0.00121	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Fluorouracil—pancreatic cancer	0.000266	0.00121	CcSEcCtD
Nevirapine—Asthenia—Sunitinib—pancreatic cancer	0.000266	0.0012	CcSEcCtD
Nevirapine—Decreased appetite—Irinotecan—pancreatic cancer	0.000265	0.0012	CcSEcCtD
Nevirapine—Somnolence—Gemcitabine—pancreatic cancer	0.000264	0.0012	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Irinotecan—pancreatic cancer	0.000264	0.00119	CcSEcCtD
Nevirapine—Fatigue—Irinotecan—pancreatic cancer	0.000263	0.00119	CcSEcCtD
Nevirapine—Paraesthesia—Fluorouracil—pancreatic cancer	0.000262	0.00119	CcSEcCtD
Nevirapine—Pruritus—Sunitinib—pancreatic cancer	0.000262	0.00119	CcSEcCtD
Nevirapine—Pain—Irinotecan—pancreatic cancer	0.000261	0.00118	CcSEcCtD
Nevirapine—Toxic epidermal necrolysis—Epirubicin—pancreatic cancer	0.000261	0.00118	CcSEcCtD
Nevirapine—Aspartate aminotransferase increased—Epirubicin—pancreatic cancer	0.000261	0.00118	CcSEcCtD
Nevirapine—Somnolence—Fluorouracil—pancreatic cancer	0.00026	0.00118	CcSEcCtD
Nevirapine—Face oedema—Doxorubicin—pancreatic cancer	0.000259	0.00117	CcSEcCtD
Nevirapine—Erythema—Docetaxel—pancreatic cancer	0.000259	0.00117	CcSEcCtD
Nevirapine—Decreased appetite—Gemcitabine—pancreatic cancer	0.000258	0.00117	CcSEcCtD
Nevirapine—Nausea—Tamoxifen—pancreatic cancer	0.000257	0.00116	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	0.000257	0.00116	CcSEcCtD
Nevirapine—Fatigue—Gemcitabine—pancreatic cancer	0.000256	0.00116	CcSEcCtD
Nevirapine—Alanine aminotransferase increased—Epirubicin—pancreatic cancer	0.000255	0.00116	CcSEcCtD
Nevirapine—Pain—Gemcitabine—pancreatic cancer	0.000254	0.00115	CcSEcCtD
Nevirapine—Nausea—Erlotinib—pancreatic cancer	0.000254	0.00115	CcSEcCtD
Nevirapine—Decreased appetite—Fluorouracil—pancreatic cancer	0.000254	0.00115	CcSEcCtD
Nevirapine—Diarrhoea—Sunitinib—pancreatic cancer	0.000254	0.00115	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	0.000252	0.00114	CcSEcCtD
Nevirapine—Feeling abnormal—Irinotecan—pancreatic cancer	0.000252	0.00114	CcSEcCtD
Nevirapine—Pain—Fluorouracil—pancreatic cancer	0.00025	0.00113	CcSEcCtD
Nevirapine—Gastrointestinal pain—Irinotecan—pancreatic cancer	0.00025	0.00113	CcSEcCtD
Nevirapine—Eosinophilia—Epirubicin—pancreatic cancer	0.000248	0.00112	CcSEcCtD
Nevirapine—Liver function test abnormal—Doxorubicin—pancreatic cancer	0.000247	0.00112	CcSEcCtD
Nevirapine—Pancreatitis—Epirubicin—pancreatic cancer	0.000245	0.00111	CcSEcCtD
Nevirapine—Feeling abnormal—Gemcitabine—pancreatic cancer	0.000245	0.00111	CcSEcCtD
Nevirapine—Abdominal pain—Irinotecan—pancreatic cancer	0.000241	0.00109	CcSEcCtD
Nevirapine—Body temperature increased—Irinotecan—pancreatic cancer	0.000241	0.00109	CcSEcCtD
Nevirapine—Toxic epidermal necrolysis—Doxorubicin—pancreatic cancer	0.000241	0.00109	CcSEcCtD
Nevirapine—Aspartate aminotransferase increased—Doxorubicin—pancreatic cancer	0.000241	0.00109	CcSEcCtD
Nevirapine—Feeling abnormal—Fluorouracil—pancreatic cancer	0.000241	0.00109	CcSEcCtD
Nevirapine—Anaemia—Docetaxel—pancreatic cancer	0.000239	0.00108	CcSEcCtD
Nevirapine—Alanine aminotransferase increased—Doxorubicin—pancreatic cancer	0.000236	0.00107	CcSEcCtD
Nevirapine—Vomiting—Sunitinib—pancreatic cancer	0.000236	0.00107	CcSEcCtD
Nevirapine—Body temperature increased—Gemcitabine—pancreatic cancer	0.000235	0.00107	CcSEcCtD
Nevirapine—Neutropenia—Epirubicin—pancreatic cancer	0.000234	0.00106	CcSEcCtD
Nevirapine—Rash—Sunitinib—pancreatic cancer	0.000234	0.00106	CcSEcCtD
Nevirapine—Dermatitis—Sunitinib—pancreatic cancer	0.000233	0.00106	CcSEcCtD
Nevirapine—Urticaria—Fluorouracil—pancreatic cancer	0.000232	0.00105	CcSEcCtD
Nevirapine—Headache—Sunitinib—pancreatic cancer	0.000232	0.00105	CcSEcCtD
Nevirapine—Body temperature increased—Fluorouracil—pancreatic cancer	0.000231	0.00105	CcSEcCtD
Nevirapine—Eosinophilia—Doxorubicin—pancreatic cancer	0.000229	0.00104	CcSEcCtD
Nevirapine—Pancreatitis—Doxorubicin—pancreatic cancer	0.000227	0.00103	CcSEcCtD
Nevirapine—Hyperglycaemia—Epirubicin—pancreatic cancer	0.000226	0.00102	CcSEcCtD
Nevirapine—Hypersensitivity—Irinotecan—pancreatic cancer	0.000225	0.00102	CcSEcCtD
Nevirapine—Stevens-Johnson syndrome—Epirubicin—pancreatic cancer	0.000221	0.001	CcSEcCtD
Nevirapine—Arthralgia—Docetaxel—pancreatic cancer	0.00022	0.000998	CcSEcCtD
Nevirapine—Myalgia—Docetaxel—pancreatic cancer	0.00022	0.000998	CcSEcCtD
Nevirapine—Nausea—Sunitinib—pancreatic cancer	0.00022	0.000998	CcSEcCtD
Nevirapine—Renal failure—Epirubicin—pancreatic cancer	0.000219	0.000994	CcSEcCtD
Nevirapine—Asthenia—Irinotecan—pancreatic cancer	0.000219	0.000993	CcSEcCtD
Nevirapine—Neuropathy peripheral—Epirubicin—pancreatic cancer	0.000219	0.000991	CcSEcCtD
Nevirapine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	0.000219	0.000991	CcSEcCtD
Nevirapine—Jaundice—Epirubicin—pancreatic cancer	0.000218	0.000986	CcSEcCtD
Nevirapine—Conjunctivitis—Epirubicin—pancreatic cancer	0.000217	0.000983	CcSEcCtD
Nevirapine—Neutropenia—Doxorubicin—pancreatic cancer	0.000217	0.000981	CcSEcCtD
Nevirapine—Hypersensitivity—Fluorouracil—pancreatic cancer	0.000215	0.000976	CcSEcCtD
Nevirapine—Asthenia—Gemcitabine—pancreatic cancer	0.000213	0.000967	CcSEcCtD
Nevirapine—Hepatobiliary disease—Epirubicin—pancreatic cancer	0.000211	0.000956	CcSEcCtD
Nevirapine—Oedema—Docetaxel—pancreatic cancer	0.000211	0.000956	CcSEcCtD
Nevirapine—Anaphylactic shock—Docetaxel—pancreatic cancer	0.000211	0.000956	CcSEcCtD
Nevirapine—Pruritus—Gemcitabine—pancreatic cancer	0.00021	0.000953	CcSEcCtD
Nevirapine—Hyperglycaemia—Doxorubicin—pancreatic cancer	0.000209	0.000947	CcSEcCtD
Nevirapine—Diarrhoea—Irinotecan—pancreatic cancer	0.000209	0.000946	CcSEcCtD
Nevirapine—Agranulocytosis—Epirubicin—pancreatic cancer	0.000208	0.000944	CcSEcCtD
Nevirapine—Nervous system disorder—Docetaxel—pancreatic cancer	0.000207	0.000938	CcSEcCtD
Nevirapine—Pruritus—Fluorouracil—pancreatic cancer	0.000207	0.000937	CcSEcCtD
Nevirapine—Thrombocytopenia—Docetaxel—pancreatic cancer	0.000207	0.000936	CcSEcCtD
Nevirapine—Skin disorder—Docetaxel—pancreatic cancer	0.000205	0.000929	CcSEcCtD
Nevirapine—Stevens-Johnson syndrome—Doxorubicin—pancreatic cancer	0.000205	0.000928	CcSEcCtD
Nevirapine—Diarrhoea—Gemcitabine—pancreatic cancer	0.000203	0.000922	CcSEcCtD
Nevirapine—Renal failure—Doxorubicin—pancreatic cancer	0.000203	0.00092	CcSEcCtD
Nevirapine—Neuropathy peripheral—Doxorubicin—pancreatic cancer	0.000202	0.000917	CcSEcCtD
Nevirapine—Jaundice—Doxorubicin—pancreatic cancer	0.000201	0.000912	CcSEcCtD
Nevirapine—Anorexia—Docetaxel—pancreatic cancer	0.000201	0.000912	CcSEcCtD
Nevirapine—Conjunctivitis—Doxorubicin—pancreatic cancer	0.000201	0.00091	CcSEcCtD
Nevirapine—Hepatitis—Epirubicin—pancreatic cancer	0.0002	0.000908	CcSEcCtD
Nevirapine—Diarrhoea—Fluorouracil—pancreatic cancer	0.0002	0.000907	CcSEcCtD
Nevirapine—Connective tissue disorder—Epirubicin—pancreatic cancer	0.000197	0.000892	CcSEcCtD
Nevirapine—Hepatobiliary disease—Doxorubicin—pancreatic cancer	0.000195	0.000885	CcSEcCtD
Nevirapine—Vomiting—Irinotecan—pancreatic cancer	0.000194	0.00088	CcSEcCtD
Nevirapine—Agranulocytosis—Doxorubicin—pancreatic cancer	0.000193	0.000873	CcSEcCtD
Nevirapine—Rash—Irinotecan—pancreatic cancer	0.000192	0.000872	CcSEcCtD
Nevirapine—Dermatitis—Irinotecan—pancreatic cancer	0.000192	0.000871	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	0.000192	0.000871	CcSEcCtD
Nevirapine—Headache—Irinotecan—pancreatic cancer	0.000191	0.000867	CcSEcCtD
Nevirapine—Paraesthesia—Docetaxel—pancreatic cancer	0.000189	0.000859	CcSEcCtD
Nevirapine—Erythema multiforme—Epirubicin—pancreatic cancer	0.000189	0.000858	CcSEcCtD
Nevirapine—Vomiting—Gemcitabine—pancreatic cancer	0.000189	0.000857	CcSEcCtD
Nevirapine—Somnolence—Docetaxel—pancreatic cancer	0.000188	0.00085	CcSEcCtD
Nevirapine—Rash—Gemcitabine—pancreatic cancer	0.000187	0.00085	CcSEcCtD
Nevirapine—Dermatitis—Gemcitabine—pancreatic cancer	0.000187	0.000849	CcSEcCtD
Nevirapine—Headache—Gemcitabine—pancreatic cancer	0.000186	0.000844	CcSEcCtD
Nevirapine—Vomiting—Fluorouracil—pancreatic cancer	0.000186	0.000842	CcSEcCtD
Nevirapine—Hepatitis—Doxorubicin—pancreatic cancer	0.000185	0.00084	CcSEcCtD
Nevirapine—Rash—Fluorouracil—pancreatic cancer	0.000184	0.000835	CcSEcCtD
Nevirapine—Dermatitis—Fluorouracil—pancreatic cancer	0.000184	0.000835	CcSEcCtD
Nevirapine—Decreased appetite—Docetaxel—pancreatic cancer	0.000183	0.000831	CcSEcCtD
Nevirapine—Headache—Fluorouracil—pancreatic cancer	0.000183	0.00083	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.000182	0.000826	CcSEcCtD
Nevirapine—Connective tissue disorder—Doxorubicin—pancreatic cancer	0.000182	0.000825	CcSEcCtD
Nevirapine—Fatigue—Docetaxel—pancreatic cancer	0.000182	0.000824	CcSEcCtD
Nevirapine—Nausea—Irinotecan—pancreatic cancer	0.000181	0.000822	CcSEcCtD
Nevirapine—Immune system disorder—Epirubicin—pancreatic cancer	0.000181	0.00082	CcSEcCtD
Nevirapine—Pain—Docetaxel—pancreatic cancer	0.00018	0.000818	CcSEcCtD
Nevirapine—Nausea—Gemcitabine—pancreatic cancer	0.000177	0.0008	CcSEcCtD
Nevirapine—Erythema multiforme—Doxorubicin—pancreatic cancer	0.000175	0.000794	CcSEcCtD
Nevirapine—Erythema—Epirubicin—pancreatic cancer	0.000174	0.00079	CcSEcCtD
Nevirapine—Feeling abnormal—Docetaxel—pancreatic cancer	0.000174	0.000788	CcSEcCtD
Nevirapine—Nausea—Fluorouracil—pancreatic cancer	0.000174	0.000787	CcSEcCtD
Nevirapine—Gastrointestinal pain—Docetaxel—pancreatic cancer	0.000173	0.000782	CcSEcCtD
Nevirapine—Immune system disorder—Doxorubicin—pancreatic cancer	0.000167	0.000759	CcSEcCtD
Nevirapine—Abdominal pain—Docetaxel—pancreatic cancer	0.000167	0.000756	CcSEcCtD
Nevirapine—Body temperature increased—Docetaxel—pancreatic cancer	0.000167	0.000756	CcSEcCtD
Nevirapine—Ill-defined disorder—Epirubicin—pancreatic cancer	0.000162	0.000733	CcSEcCtD
Nevirapine—Erythema—Doxorubicin—pancreatic cancer	0.000161	0.000731	CcSEcCtD
Nevirapine—Anaemia—Epirubicin—pancreatic cancer	0.000161	0.00073	CcSEcCtD
Nevirapine—Malaise—Epirubicin—pancreatic cancer	0.000157	0.000713	CcSEcCtD
Nevirapine—Hypersensitivity—Docetaxel—pancreatic cancer	0.000155	0.000705	CcSEcCtD
Nevirapine—Asthenia—Docetaxel—pancreatic cancer	0.000151	0.000686	CcSEcCtD
Nevirapine—Ill-defined disorder—Doxorubicin—pancreatic cancer	0.00015	0.000678	CcSEcCtD
Nevirapine—Pruritus—Docetaxel—pancreatic cancer	0.000149	0.000677	CcSEcCtD
Nevirapine—Anaemia—Doxorubicin—pancreatic cancer	0.000149	0.000676	CcSEcCtD
Nevirapine—Arthralgia—Epirubicin—pancreatic cancer	0.000148	0.000673	CcSEcCtD
Nevirapine—Myalgia—Epirubicin—pancreatic cancer	0.000148	0.000673	CcSEcCtD
Nevirapine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	0.000147	0.000668	CcSEcCtD
Nevirapine—Discomfort—Epirubicin—pancreatic cancer	0.000147	0.000665	CcSEcCtD
Nevirapine—Malaise—Doxorubicin—pancreatic cancer	0.000146	0.000659	CcSEcCtD
Nevirapine—Diarrhoea—Docetaxel—pancreatic cancer	0.000144	0.000654	CcSEcCtD
Nevirapine—Oedema—Epirubicin—pancreatic cancer	0.000142	0.000645	CcSEcCtD
Nevirapine—Anaphylactic shock—Epirubicin—pancreatic cancer	0.000142	0.000645	CcSEcCtD
Nevirapine—Nervous system disorder—Epirubicin—pancreatic cancer	0.00014	0.000633	CcSEcCtD
Nevirapine—Thrombocytopenia—Epirubicin—pancreatic cancer	0.000139	0.000632	CcSEcCtD
Nevirapine—Skin disorder—Epirubicin—pancreatic cancer	0.000138	0.000627	CcSEcCtD
Nevirapine—Arthralgia—Doxorubicin—pancreatic cancer	0.000137	0.000623	CcSEcCtD
Nevirapine—Myalgia—Doxorubicin—pancreatic cancer	0.000137	0.000623	CcSEcCtD
Nevirapine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	0.000136	0.000618	CcSEcCtD
Nevirapine—Discomfort—Doxorubicin—pancreatic cancer	0.000136	0.000615	CcSEcCtD
Nevirapine—Anorexia—Epirubicin—pancreatic cancer	0.000136	0.000615	CcSEcCtD
Nevirapine—Vomiting—Docetaxel—pancreatic cancer	0.000134	0.000608	CcSEcCtD
Nevirapine—Rash—Docetaxel—pancreatic cancer	0.000133	0.000603	CcSEcCtD
Nevirapine—Dermatitis—Docetaxel—pancreatic cancer	0.000133	0.000602	CcSEcCtD
Nevirapine—Headache—Docetaxel—pancreatic cancer	0.000132	0.000599	CcSEcCtD
Nevirapine—Oedema—Doxorubicin—pancreatic cancer	0.000132	0.000597	CcSEcCtD
Nevirapine—Anaphylactic shock—Doxorubicin—pancreatic cancer	0.000132	0.000597	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	0.00013	0.000588	CcSEcCtD
Nevirapine—Nervous system disorder—Doxorubicin—pancreatic cancer	0.000129	0.000585	CcSEcCtD
Nevirapine—Thrombocytopenia—Doxorubicin—pancreatic cancer	0.000129	0.000584	CcSEcCtD
Nevirapine—Skin disorder—Doxorubicin—pancreatic cancer	0.000128	0.00058	CcSEcCtD
Nevirapine—Paraesthesia—Epirubicin—pancreatic cancer	0.000128	0.000579	CcSEcCtD
Nevirapine—Somnolence—Epirubicin—pancreatic cancer	0.000127	0.000573	CcSEcCtD
Nevirapine—Anorexia—Doxorubicin—pancreatic cancer	0.000126	0.000569	CcSEcCtD
Nevirapine—Nausea—Docetaxel—pancreatic cancer	0.000125	0.000568	CcSEcCtD
Nevirapine—Decreased appetite—Epirubicin—pancreatic cancer	0.000124	0.000561	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Epirubicin—pancreatic cancer	0.000123	0.000557	CcSEcCtD
Nevirapine—Fatigue—Epirubicin—pancreatic cancer	0.000123	0.000556	CcSEcCtD
Nevirapine—Pain—Epirubicin—pancreatic cancer	0.000122	0.000552	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	0.00012	0.000544	CcSEcCtD
Nevirapine—Paraesthesia—Doxorubicin—pancreatic cancer	0.000118	0.000536	CcSEcCtD
Nevirapine—Feeling abnormal—Epirubicin—pancreatic cancer	0.000117	0.000532	CcSEcCtD
Nevirapine—Somnolence—Doxorubicin—pancreatic cancer	0.000117	0.000531	CcSEcCtD
Nevirapine—Gastrointestinal pain—Epirubicin—pancreatic cancer	0.000116	0.000527	CcSEcCtD
Nevirapine—Decreased appetite—Doxorubicin—pancreatic cancer	0.000114	0.000519	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	0.000114	0.000515	CcSEcCtD
Nevirapine—Fatigue—Doxorubicin—pancreatic cancer	0.000114	0.000515	CcSEcCtD
Nevirapine—Urticaria—Epirubicin—pancreatic cancer	0.000113	0.000512	CcSEcCtD
Nevirapine—Pain—Doxorubicin—pancreatic cancer	0.000113	0.00051	CcSEcCtD
Nevirapine—Abdominal pain—Epirubicin—pancreatic cancer	0.000113	0.00051	CcSEcCtD
Nevirapine—Body temperature increased—Epirubicin—pancreatic cancer	0.000113	0.00051	CcSEcCtD
Nevirapine—Feeling abnormal—Doxorubicin—pancreatic cancer	0.000109	0.000492	CcSEcCtD
Nevirapine—Gastrointestinal pain—Doxorubicin—pancreatic cancer	0.000108	0.000488	CcSEcCtD
Nevirapine—Hypersensitivity—Epirubicin—pancreatic cancer	0.000105	0.000475	CcSEcCtD
Nevirapine—Urticaria—Doxorubicin—pancreatic cancer	0.000105	0.000474	CcSEcCtD
Nevirapine—Abdominal pain—Doxorubicin—pancreatic cancer	0.000104	0.000472	CcSEcCtD
Nevirapine—Body temperature increased—Doxorubicin—pancreatic cancer	0.000104	0.000472	CcSEcCtD
Nevirapine—Asthenia—Epirubicin—pancreatic cancer	0.000102	0.000463	CcSEcCtD
Nevirapine—Pruritus—Epirubicin—pancreatic cancer	0.000101	0.000456	CcSEcCtD
Nevirapine—Diarrhoea—Epirubicin—pancreatic cancer	9.74e-05	0.000441	CcSEcCtD
Nevirapine—Hypersensitivity—Doxorubicin—pancreatic cancer	9.7e-05	0.00044	CcSEcCtD
Nevirapine—Asthenia—Doxorubicin—pancreatic cancer	9.45e-05	0.000428	CcSEcCtD
Nevirapine—Pruritus—Doxorubicin—pancreatic cancer	9.32e-05	0.000422	CcSEcCtD
Nevirapine—Vomiting—Epirubicin—pancreatic cancer	9.05e-05	0.00041	CcSEcCtD
Nevirapine—Diarrhoea—Doxorubicin—pancreatic cancer	9.01e-05	0.000408	CcSEcCtD
Nevirapine—Rash—Epirubicin—pancreatic cancer	8.97e-05	0.000407	CcSEcCtD
Nevirapine—Dermatitis—Epirubicin—pancreatic cancer	8.96e-05	0.000406	CcSEcCtD
Nevirapine—Headache—Epirubicin—pancreatic cancer	8.92e-05	0.000404	CcSEcCtD
Nevirapine—Nausea—Epirubicin—pancreatic cancer	8.45e-05	0.000383	CcSEcCtD
Nevirapine—Vomiting—Doxorubicin—pancreatic cancer	8.37e-05	0.000379	CcSEcCtD
Nevirapine—Rash—Doxorubicin—pancreatic cancer	8.3e-05	0.000376	CcSEcCtD
Nevirapine—Dermatitis—Doxorubicin—pancreatic cancer	8.3e-05	0.000376	CcSEcCtD
Nevirapine—Headache—Doxorubicin—pancreatic cancer	8.25e-05	0.000374	CcSEcCtD
Nevirapine—Nausea—Doxorubicin—pancreatic cancer	7.82e-05	0.000354	CcSEcCtD
